Re: "Re-biopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer with EGFR/ALK/ROS Oncogenic Driver Progression after Optimal Targeted Therapy: A Multicenter Real-World Analysis". — SciRadar